RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Bio-Techne Stock

Bio-Techne Net Income 2025

Bio-Techne Net Income

306.65 M USD

Ticker

TECH

ISIN

US09073M1045

WKN

A12ENG

In 2025, Bio-Techne's profit amounted to 306.65 M USD, a 82.45% increase from the 168.07 M USD profit recorded in the previous year.

The Bio-Techne Net Income history

YEARNET INCOME (undefined USD)
2029e562.38
2028e504.03
2027e407.48
2026e355.85
2025e306.65
2024168.07
2023285.2
2022271.9
2021140.3
2020229.1
201996
2018126.2
201776.1
2016104.5
2015107.7
2014110.9
2013112.6
2012112.3
2011112.3
2010109.8
2009105.2
2008103.6
200785.1
200673.4
200566.1

Bio-Techne Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Bio-Techne, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Bio-Techne from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Bio-Techne’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Bio-Techne. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Bio-Techne’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Bio-Techne’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Bio-Techne’s growth potential.

Bio-Techne Revenue, EBIT and net profit per share

DateBio-Techne RevenueBio-Techne EBITBio-Techne Net Income
2029e1.93 B undefined0 undefined562.38 M undefined
2028e1.74 B undefined635.89 M undefined504.03 M undefined
2027e1.52 B undefined504.36 M undefined407.48 M undefined
2026e1.36 B undefined449.23 M undefined355.85 M undefined
2025e1.25 B undefined384.71 M undefined306.65 M undefined
20241.16 B undefined248.46 M undefined168.07 M undefined
20231.14 B undefined293.6 M undefined285.2 M undefined
20221.11 B undefined298.2 M undefined271.9 M undefined
2021931 M undefined244.9 M undefined140.3 M undefined
2020738.7 M undefined150.7 M undefined229.1 M undefined
2019714 M undefined149 M undefined96 M undefined
2018643 M undefined161 M undefined126.2 M undefined
2017563 M undefined146.4 M undefined76.1 M undefined
2016499 M undefined153.4 M undefined104.5 M undefined
2015452.2 M undefined151.5 M undefined107.7 M undefined
2014357.8 M undefined159.8 M undefined110.9 M undefined
2013310.6 M undefined158.5 M undefined112.6 M undefined
2012314.6 M undefined170.5 M undefined112.3 M undefined
2011290 M undefined165.8 M undefined112.3 M undefined
2010269 M undefined156.3 M undefined109.8 M undefined
2009264 M undefined150.8 M undefined105.2 M undefined
2008257.4 M undefined144.3 M undefined103.6 M undefined
2007223.5 M undefined124.2 M undefined85.1 M undefined
2006202.6 M undefined108.5 M undefined73.4 M undefined
2005178.7 M undefined97.8 M undefined66.1 M undefined

Bio-Techne stock margins

The Bio-Techne margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Bio-Techne. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Bio-Techne.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Bio-Techne's sales revenue. A higher gross margin percentage indicates that the Bio-Techne retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Bio-Techne's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Bio-Techne's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Bio-Techne's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Bio-Techne. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Bio-Techne's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Bio-Techne Margin History

Bio-Techne Gross marginBio-Techne Profit marginBio-Techne EBIT marginBio-Techne Profit margin
2029e66.41 %0 %29.11 %
2028e66.41 %36.44 %28.88 %
2027e66.41 %33.27 %26.88 %
2026e66.41 %32.96 %26.11 %
2025e66.41 %30.85 %24.59 %
202466.41 %21.44 %14.5 %
202367.72 %25.83 %25.09 %
202268.42 %26.97 %24.59 %
202167.98 %26.31 %15.07 %
202065.41 %20.4 %31.01 %
201966.32 %20.87 %13.45 %
201867.2 %25.04 %19.63 %
201766.52 %26 %13.52 %
201667.47 %30.74 %20.94 %
201567.96 %33.5 %23.82 %
201470.26 %44.66 %30.99 %
201374.4 %51.03 %36.25 %
201275.91 %54.2 %35.7 %
201177.86 %57.17 %38.72 %
201079.59 %58.1 %40.82 %
200978.79 %57.12 %39.85 %
200879.45 %56.06 %40.25 %
200779.11 %55.57 %38.08 %
200677.44 %53.55 %36.23 %
200579.35 %54.73 %36.99 %

Bio-Techne Aktienanalyse

What does Bio-Techne do?

Bio-Techne Corp is a global company specializing in the research and development of innovative products and solutions in the field of biosciences. The company was founded in 1976 in Minneapolis and was formerly known as Techne Corporation. Since then, it has grown into an internationally renowned company through its numerous acquisitions and mergers. The company is headquartered in Minneapolis, Minnesota, USA. The business philosophy of Bio-Techne Corp is to help bioscientific researchers and clinicians around the world perform their work more effectively, efficiently, and quickly. The company works closely with its customers to provide them with suitable products and services, thereby developing innovative solutions to the challenges in bioscience. Bio-Techne Corp has various business segments, including protein platforms, diagnostics, genetic analysis, clinical controls, cell culture products, and research reagents. Each business segment offers a variety of products and services to support researchers and clinicians in their work. A key business segment of Bio-Techne Corp is the protein platform, which offers a comprehensive range of proteins, antibodies, and corresponding detection reagents. The company is known for its high-quality proteins and antibodies, which contribute to improving the research of diseases such as cancer, diabetes, and neurological and immunological disorders. Another important business segment of Bio-Techne Corp is diagnostics. Here, the company offers a wide range of clinical diagnostic products, such as tests for analyzing urea, creatinine, and bone density. The company's products help clinicians make precise diagnoses and treat patients more effectively. The genetic analysis segment offers DNA sequencing, gene expression, and genome-wide analysis products and services. These tools enable researchers to better understand the functioning of the human body by exploring the underlying genetic changes. The clinical controls segment offers product and service offerings that improve the reliability and accuracy of diagnostic systems. The company works closely with medical facilities to provide diagnostic solutions that deliver fast and accurate results. The cell culture products segment offers a complete range of solutions for cell cultivation and growth. The offering ranges from basic nutrient media and additives to culture vessels and accessories. The company's products enable researchers to culture cells in a controlled environment and under precise conditions. The last segment of Bio-Techne Corp includes research reagents. Here, the company offers a wide range of reagents used for protein, antibody, and cell function analysis and research. The products meet the needs of researchers in modern bioscience. In summary, Bio-Techne Corp is a company specialized in developing innovative solutions in bioscience, advancing science and medicine. With its products and services offered in various sectors, the company successfully helps researchers and clinicians perform their work faster, more effectively, and cost-efficiently. Bio-Techne ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Bio-Techne's Profit Margins

The profit margins of Bio-Techne represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Bio-Techne's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Bio-Techne's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Bio-Techne's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Bio-Techne’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Bio-Techne stock

How much profit has Bio-Techne made this year?

Bio-Techne has made 306.65 M USD this year.

How has the profit developed compared to last year?

The profit has increased by 82.45% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Bio-Techne publish its earnings?

Bio-Techne publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Bio-Techne?

The profits of Bio-Techne are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Bio-Techne?

You can learn more about the earnings of Bio-Techne by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Bio-Techne pay?

Over the past 12 months, Bio-Techne paid a dividend of 0.4 USD . This corresponds to a dividend yield of about 0.55 %. For the coming 12 months, Bio-Techne is expected to pay a dividend of 0.39 USD.

What is the dividend yield of Bio-Techne?

The current dividend yield of Bio-Techne is 0.55 %.

When does Bio-Techne pay dividends?

Bio-Techne pays a quarterly dividend. This is distributed in the months of March, July, October, December.

How secure is the dividend of Bio-Techne?

Bio-Techne paid dividends every year for the past 22 years.

What is the dividend of Bio-Techne?

For the upcoming 12 months, dividends amounting to 0.39 USD are expected. This corresponds to a dividend yield of 0.54 %.

In which sector is Bio-Techne located?

Bio-Techne is assigned to the 'Health' sector.

Wann musste ich die Aktien von Bio-Techne kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Bio-Techne from 11/22/2024 amounting to 0.08 USD, you needed to have the stock in your portfolio before the ex-date on 11/8/2024.

When did Bio-Techne pay the last dividend?

The last dividend was paid out on 11/22/2024.

What was the dividend of Bio-Techne in the year 2024?

In the year 2024, Bio-Techne distributed 0.4 USD as dividends.

In which currency does Bio-Techne pay out the dividend?

The dividends of Bio-Techne are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Bio-Techne

Our stock analysis for Bio-Techne Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bio-Techne Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.